F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases. Founded by David Denning in 1998, F2G is backed by investors that include Innovate UK, European Investment Bank, Novo Holdings, Aisling Capital, and Cowen Healthcare Investments and is headquartered in Manchester.
FOUNDED:
1998
INDUSTRY:
Biotechnology, Genetics, Medical, Pharmaceutical
FOUNDERS:
David Denning
You are seconds away from signing up for the hottest list in New York Tech!
Join the millions and keep up with the stories shaping entrepreneurship. Sign up today.
